Table 1.

Patient characteristics

Haplo donorMSDMUD TCD+MUD TCD−P
Number of patients132525403378
Number of centers24864551
Reporting registry<.001
 CIBMTR97 (73)353 (67)166 (41)263 (70)
 EBMT35 (27)172 (33)237 (59)115 (30)
Patient age, median (range), y58 (20-75)55 (19-73)55 (19-75)56 (23-73)<.001
Patients ≥60 y59 (45)135 (26)121 (30)134 (35)
Male sex86 (65)323 (62)259 (64)218 (58).22
KPS ≥9096 (73)325 (62)249 (62)216 (57).003
KPS missing5 (4)24 (4)26 (6)10 (2)
HCT-CI<.001
 033 (25)119 (23)54 (13)63 (17)
 1-231 (23)112 (21)75 (19)84 (22)
 ≥336 (27)137 (26)85 (21)125 (33)
 Missing*33 (25)157 (30)189 (47)106 (28)
Patient race<.001
 White91 (69)349 (66)258 (64)282 (75)
 African American15 (11)12 (2)2 (<1)5 (1)
 Other2 (2)36 (8)2 (<1)7 (1)
 Missing24 (18)128 (24)141 (36)84 (22)
Time from diagnosis to transplant, median (range), mo22 (<1-173)26 (2-386)24 (2-340)28 (2-299).18
Previous auto-HCT56 (42)288 (55)237 (59)229 (61).002
Remission status at HCT.72
 Complete63 (48)217 (41)179 (44)171 (45)
 Partial45 (34)181 (34)133 (33)133 (35)
 Refractory23 (17)109 (21)74 (18)64 (17)
 Untreated/unknown1 (<1)18 (4)17 (5)10 (3)
TBI in conditioning114 (86)109 (21)30 (7)121 (32)<.001
Graft type<.001
 Bone marrow100 (76)10 (2)30 (7)20 (5)
 Peripheral blood32 (24)515 (98)373 (93)358 (95)
CMV status
 D+/R−11 (8)38 (7)21 (5)31 (8)<.001
 Missing64 (49)257 (49)240 (58)120 (31)
D-R sex match<.001
 Female-male42 (32)139 (26)95 (24)66 (17)
 Other90 (68)386 (74)306 (75)311 (82)
 Missing02 (<1)2 (<1)1 (<1)
GVHD prophylaxis<.001
 PTCy132N/AN/AN/A
 CNI + MMF ± othersN/A191 (36)158 (39)159 (42)
 CNI + MTX ± othersN/A236 (45)154 (38)150 (40)
 CNI + othersN/A98 (19)91 (23)69 (18)
Follow-up of survivors, median (range), mo49 (12-73)48 (2-97)49 (3-100)39 (4-96)
  • Values in parentheses represent percentages if not indicated otherwise.

  • A/C, anti–thymocyte globulin/alemtuzumab; CMV, cytomegalovirus; D-R, donor-recipient; HCT-CI, hematopoietic cell transplant-comorbidity index; KPS, Karnofsky performance score; MMF, mycophenolate mofetil; MTX, methotrexate; N/A, not applicable; w, with; w/o, without.

  • * EBMT does not collect this variable for minimal essential data (MED-A) patients.

  • Details of conditioning regimens are given in supplemental Table 2.